Recent

% | $
Quotes you view appear here for quick access.

Novo Nordisk A/S Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • magmacity1 magmacity1 Nov 8, 2012 3:58 PM Flag

    Finally!! Up to max

    Some findings for sure. Nov 8 (Reuters) - Novo Nordisk A/S : * Hypoglycemia risk of Novo nordisk's degludec insulin in trials did

    not appear significantly higher or lower than oher insulins -- chair of FDA

    advisory panel * Balance seemed reasonable between efficacy and hypoglycemia in studies of

    degludec - chair of FDA advisory panel * 24-hr half life of degludec makes it unique in terms of long, stable

    duration, dosing flexibility - chair of FDA advisory panel

    Sentiment: Strong Buy

 
NVO
53.14+3.32(+6.66%)3:52 PMEDT